Inhibrx - Rasio nilai perusahaan marang dodolan INBX

Simbol resmi perusahaan inhibrx.com (INBX)

Marc Lapierre effectively coordinates the development of complex biologics while attracting research investments. The price-to-sales multiple illustrates the market response, where the 589875.00 level indicates the state of the parameter. The business relies on outsourced production via a network of CMOs, maintaining a flexible model. Meanwhile, the financial stability of Inhibrx Biosciences (INBX) completely eliminates dependence on macroeconomic fluctuations.

Inhibrx Corp (INBX): Nilai perusahaan marang pendapatan saka 23.11.2025 nganti 20.11.2026

Inhibrx Biosciences Inc - rincian analitis lan metrik utama (INBX)

Pambiji fundamental perusahaan:INBX, inhibrx.com
Produk sing diprodhuksi Inhibrx

The stability of the highly qualified R&D core at Inhibrx Biosciences (INBX) ensures sustainable intellectual capital. Analyzing the firm's valuation via the EV/Sales multiple, an investor sees the ratio of the business's enterprise value, including net debt, to annual sales volume. This metric eliminates the impact of leverage, demonstrating the actual value of one dollar of revenue. The trend of this indicator reflects market expectations for future earnings. The fundamental strength of the personnel minimizes operational risks at the current capitalization.

Analisis pesaing

Multiplikator nilai perusahaan marang pendapatan Incyte Corporation|HCM (HUTCHMED Corp) - Nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang dodolan Nuvation Pharma NUVB|Nilai perusahaan marang pendapatan DAWN|Multiplikator nilai perusahaan marang pendapatan Monopar Therapeutics MNPR|Nilai perusahaan marang pendapatan IMAB (I-Mab Biopharma Co., Ltd.)|FENC (Fennec Pharmaceuticals Inc.) - Nilai bisnis marang pendapatan|Heron Therapeutics, Inc. - Nilai perusahaan marang pendapatan|Koefisien nilai perusahaan marang pendapatan NVCT (Nuvectis Pharma)|Coherus BioSciences, Inc. - Multiplikator EV/Sales|Nilai bisnis marang pendapatan CRBP (Corbus Pharma)|CRDF: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan beyondspringpharma.com (BYSI)|Rasio nilai perusahaan marang pendapatan bioatla.com|LIXT: Nilai bisnis marang pendapatan|Multiplikator EV/Sales CTXR|Multiplikator EV/Sales Cellectar Corp (CLRB)|Rasio nilai perusahaan marang pendapatan BioLineRx Corp BLRX|CANF (Can-Fite BioPharma Ltd.) - Nilai perusahaan marang volume dodolan|APRE: Nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Kazia Therapeutics Limited|Silexion Therapeutics Corp (SLXN) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan NCNA|CMRX (Chimerix, Inc.) - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Cyclacel Pharmaceuticals CYCC|G1 Therapeutics Inc. (GTHX) - Nilai bisnis marang pendapatan|KRON - Multiplikator nilai perusahaan marang pendapatan|Kintara Therapeutics, Inc. - Nilai perusahaan marang pendapatan|Koefisien nilai perusahaan marang pendapatan ONCT (Oncternal)|Portage Biotech Corp - Multiplikator EV/Sales